

Adult onset pityriasis rubra pilaris

Virendra N. Sehgal, Govind Srivastava¹, Sunil Dogra²

Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Delhi, ¹Skin Institute and School of Dermatology Greater Kailash, New Delhi, ²Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Address for correspondence: Dr. Virendra N. Sehgal, A/6, Panchwati, Delhi-110 033, India. E-mail: drsehgal@ndf.vsnl.net.in

ABSTRACT

Pityriasis rubra pilaris (PRP) has always been an intriguing topic ever since its inception. It is a group of chronic disorders characterized by reddish orange plaques with pityriasiform scaling showing follicular keratoses, palmoplantar keratoderma, and sometimes, erythroderma. It occurs all over the world but with racial variations. Its incidence might vary and the age at onset, behavior, clinical appearance, and prognosis are considered to be very important for its classification. It may manifest either as Type I classical adult onset PRP, Type II atypical adult (onset) PRP, or Type VI PRP (HIV-associated PRP pityriasis rubra pilaris) in contrast to classical juvenile (Type III) and circumscribed juvenile (Type IV) encountered among children. Its diagnosis is largely clinical with microscopic pathology being a useful supplement, but it continues to be a therapeutic dilemma. We review the epidemiology of adult onset PRP here and take stock of the prevalent treatment options.

Key Words: Adult onset, Pityriasis rubra pilaris

INTRODUCTION

Ever since the first reported case of the disease, pityriasis rubra pilaris (PRP) has remained a consistently recorded and researched entity to date.^[1-12] However, its etiology and management have remained a challenge for the treating physician. It is seen in adults (adult onset) as well as in children, and affects both the sexes. Occasionally, PRP is associated with other diseases and it was speculated that the disorder might be the result of an abnormal immune response to some antigenic stimuli.^[4] However, familial occurrence of the disease might point to some genes that predispose the individual to develop this disorder after certain precipitating events.^[13-17] The occurrence of this dermatosis in association with human immunodeficiency virus (HIV)/acquired immunodeficiency disease (AIDS) patients has sparked a dialogue as to whether or not it is yet another variant of PRP.^[18-22]

DEFINITION

Pityriasis rubra pilaris refers to a group of chronic disorders

characterized by reddish orange plaques with pityriasiform scaling showing follicular keratoses, palmoplantar keratoderma, and sometimes, erythroderma. Familial as well as acquired forms of the disease have been reported.^[23]

HISTORY

Devergie has been credited with the naming of 'pityriasis pilaris' in 1857, which received the eponym of Devergie's diseases.^[24] However, much before that, Tarral^[1] in 1835, recorded the case description of this disease in the "Rayer's^[1]-a theoretical and practical treatise on the disease of the skin" under the title of 'general psoriasis'. Devergie stressed that Tarral's case was an example of PRP, and observed that PRP might be confused with psoriasis. However, in 1889, Besnier^[25] advanced the present day name, "pityriasis rubra pilaris." Later, several authors^[26-31] recognized that PRP was of many types, and thus suggested several working classifications.^[32-37] With the advent of HIV/AIDS, its association with PRP has been noticed by many, prompting expansion of the existing classification to accommodate PRP associated with HIV as a distinct type.^[20,38-40]

How to cite this article: Sehgal VN, Srivastava G, Dogra S. Adult onset pityriasis rubra pilaris. Indian J Dermatol Venereol Leprol 2008;74:311-21.

Received: April, 2007. **Accepted:** March, 2008. **Source of Support:** Nil. **Conflict of Interest:** None Declared.

EPIDEMIOLOGY

Although PRP occurs worldwide, there are racial variations.^[2,3] Its incidence might vary-it is 1 in 5,000 in Great Britain^[34] and 1 in 50,000 in India^[31] in an outpatient setting. Both the sexes are affected equally at all ages.^[14,33] A bimodal or trimodal age distribution has been recorded with peak incidence in the 1st, 2nd and 6th decade of life.^[27,34,41-44] The majority of the cases have been acquired^[34-42] and familial occurrence is only sporadic (up to 6.5%).^[13-17,27,28,37,41,45,46] Autosomal dominant inheritance with variable penetrance is usual; however, autosomal recessive inheritance has also been described.^[47] Monozygotic twins have been observed to develop PRP.^[48] Familial PRP usually develops in childhood while acquired PRP develops in the 5th or 6th decade of life.^[32-34] The development of PRP in HIV/AIDS was recognized several years after its discovery, and might show peculiarities compared to classical adult PRP; it responds to antiretroviral therapy in most instances.

CLASSIFICATION

PRP was initially classified on the basis of the age at onset, behavior, clinical appearance, and prognosis by Griffiths^[34] in 1980 [Table 1]. The classical (type I) adult onset PRP shows a characteristic morphology and usually resolves in 3-4 years, whereas atypical adult-onset (type II) PRP is chronic, shows ichthyosiform and lamellar scales on the palms and soles, and alopecia of varying degrees.^[2,34] The association of PRP and HIV infection has recently been identified as type VI PRP and most of the cases have been

reported in young heterosexual/homosexual men.^[22] It has characteristically nodulo-cystic and lichen spinulosus-like lesions, poor prognosis, and is refractory to treatment.^[13-15,18-20,22,28] However, after the study of 168 Thai patients, Piamphongsant and Akaraphant^[37] classified the disease into four types based on the physical findings [Table 2]. However, Griffiths^[34] classification continues to be the mainstay in practice for delineating the disease.

ETIOLOGY

The exact cause of PRP is not known-the familial type usually has an autosomal dominant mode of inheritance,^[46] although recessive forms have also been recorded.^[47] Genetic factors may be important; however, family history is generally not forthcoming. Epidermal hyperactivity demonstrated by a faster growth of the nails and an increase in the thymidine labeling index from a normal 3% to a high 27%, may be observed in PRP.^[49-53] Finzi *et al*, observed a decreased level of serum retinol-binding protein in 11 PRP patients and their relatives,^[54-58] while Frazier and Hu^[59-60] and Lowenthal^[61] suggested that an abnormal vitamin A metabolism and/or vitamin A deficiency may play some role in PRP etiology. However, others^[62-64] did not find any decreased levels of vitamin A; thus, no correlation between vitamin A deficiency and dyskeratosis has been established.^[65] Interestingly, Rothman observed that vitamin A administration has often been beneficial in follicular and nonfollicular, hyperkeratotic disease even if these diseases did not originate from vitamin A deficiency.^[66]

Table 1: Pityriasis rubra pilaris-Griffith's clinical classification^[34,36]

Clinical type	Lesions' distribution	Natural course	Percentage of a cases
Classical adult	Generalized	Remission in 3-4 years	55
Atypical adult	Generalized	Chronic intractable	5
Classical juvenile	Generalized	Remission in 1-2 years.	10
Circumscribed juvenile	Localized	Unpredictable	25
Atypical juvenile	Generalized	Chronic intractable	5
PRP and human immunodeficiency virus-associated type ^[20-22,38-40]	Face and upper trunk	Refractory	On the increase

PRP - Pityriasis rubra pilaris

Table 2: Piamphongsant and Akaraphant classification of pityriasis rubra pilaris

Types	168 patients		Clinical features
	Adult	Children	
Type I	11	21	Salmon-colored, erythematous, thick plaques on the palms and soles, extending to dorsopalmar and plantar junctions
Type II	27	59	Scaly erythematous patches on the elbows and knees
Type III	16	20	Similar patches of type II (vide supra) involving large areas of the trunk, yet not generalized
Type IV	10	4	Exfoliative erythroderma associated with diffuse follicular plugging

Furthermore, bacterial superantigens have recently been incriminated in triggering some skin diseases including juvenile PRP.^[67-70] This has been corroborated by the detection of bacterial superantigens in the course of acute throat infections (*Staphylococcus aureus* and group A β *Streptococcus pyogenes*), simultaneous appearance of lesions conforming to the morphology of childhood onset/juvenile PRP, and the disappearance of lesions following administration of appropriate antibiotics. In addition, significant increases in peripheral blood mononuclear cell (PBMCs) counts against *Staphylococcal* enterotoxin B *in vitro* might suggest hyper-reactivity to some bacterial products, which may lead to childhood onset/juvenile PRP.^[68]

CLINICAL FEATURES

Adult onset PRP conforms to Griffiths^[34] type I classical adult and type II atypical adult classifications, the former being the most common. In contrast to childhood onset juvenile PRP,^[23] adult PRP typically starts on the face and scalp and promptly spreads in the cephalocaudal direction.^[2,3]

Type I classical adult onset PRP: It is characterized by follicular hyperkeratotic papules that coalesce into large, scaly, erythematous plaques, palmoplantar keratoderma, diffuse furfureous scaling of the scalp sometimes progressing into erythroderma.^[2-4,24-28] The onset is usually acute and the eruptions begin on the head, neck and upper chest as discrete, follicular papules that often coalesce to form plaques with interfollicular erythema. The spread of the lesion is characteristically in the cephalocaudal direction. The face assumes a red-orange hue with mild to moderate ectropion. The affected skin is extremely rough to touch and feels like a file.^[1] Prolonged erythema may cause resultant edema, and may precipitate a high output cardiac failure in the elderly. The palms and soles may acquire the appearance of a 'hyperkeratotic sandal', while the scalp reveals diffuse bran-like scaling. Should an erythroderma develop, a few sharply demarcated islands of unaffected skin [Figures 1A, B] are important diagnostic criteria.^[2,3,71-76] Pruritus is uncommon; nail changes (if any) are marked by thickening and yellow-brown discoloration of the nail plate, subungual hyperkeratosis, and splinter hemorrhages.^[2,3,77-79] Unlike psoriasis, nail dystrophy and pitting are minimal in PRP. The oral mucosa may be involved in a few patients, showing macular erythema, diffuse hyperkeratosis, and white streaks;^[80] hair and teeth are normal.^[2-4] Type I classical adult onset PRP runs a chronic course, three out of four cases may resolve in 1-3 years; relapses are usually uncommon.

Type II atypical adult onset PRP: It is an uncommon form

of the disease that develops in middle-aged adults with atypical morphological features deviating from those described above. These patients show an admixture of follicular hyperkeratosis and lamellar scaling [Figures 2A, B] on their skin surface.^[2-4,24,81] Areas of eczematous changes can sometimes confuse the clinical picture. The classical cephalocaudal progression is conspicuous by its absence; the occurrence of erythroderma is also unusual.

Type VI PRP (HIV-associated PRP): The occurrence of PRP in HIV/AIDS shows certain peculiarities^[20,38-40] such as a 'filiform' pattern of keratosis on the face and upper trunk, accompanied by marked acne conglobata. This type is usually recalcitrant to conventional therapy and has a poor prognosis.^[20-22,38-40] Other types are described in Table 1.

ASSOCIATED FINDINGS

Adult PRP has been found to be associated with several cutaneous and noncutaneous disorders.^[82-85] The exact significance of which is a matter of speculation. The associated disorders include vitiligo, lichen planus, alopecia universalis,^[12] Kaposi varicelliform eruption,^[86] seronegative arthritis,^[87-90] myositis,^[83] myasthenia gravis,^[91] hypothyroidism,^[82] celiac sprue,^[84] and other infections including HIV.^[20,38-40] Infrequently, internal malignancies have been recorded in adult onset PRP.^[92-95] However, prominent or increasing seborrheic keratoses seen in erythrodermic PRP does not necessarily imply an underlying malignancy.^[85,96] An intense degree of erythema in erythrodermic PRP predisposes the individual to photosensitivity and worsening of the erythema has also been recorded with UVA and UVB.^[97-99]

HISTOPATHOLOGIC FINDINGS

Adult onset PRP displays distinctive histopathological findings, which may differ according to the stage and evolution of the lesions.^[2,3] The salient criteria include: (a) alternating orthokeratosis and parakeratosis in both the vertical and horizontal directions, (b) hypergranulosis, (c), irregular acanthosis apparent in the form of short and broad rete-ridges, (d) thick suprapapillary plates, and (e) a sparse to moderate lymphocytic perivascular infiltrate in the dermis^[27,42,49,71,100] [Figure 3]. The hair follicles are dilated and filled with a dense, horny plug [Figure 4]. Munro's microabscesses and suprapapillary thinning are conspicuously absent. The differential diagnosis may often be difficult in erythrodermic patients.




Figure 1: (A) and (B) Adult onset pityriasis rubra pilaris: Type I classical adult, multiple, discrete erythematous-scaly acuminated papules, a few coalescing to form plaques. Intervening 'islands of sparing' are conspicuous



Figures 2: (A) and (B) Adult onset pityriasis rubra pilaris: Type II atypical adult, multiple, discrete erythematous-scaly papules/plaques

Walsh *et al.*^[101] found that dermatopathologists are the least (25%) accurate when scanning the sections prepared from biopsies of erythroderma of PRP origin. The dermis shows dilated capillaries with a mild to moderate infiltrate of lymphocytes and histiocytes. Acantholysis and focal acantholytic dyskeratosis have recently been recorded in adult PRP.^[94,102-104] These histological parameters are unique and different from those seen in psoriasis; Magro and Crowson^[43] found these features in 23 of the 32 biopsies from PRP. However, they were not found in any of the specimens of psoriasis.

Porter and Shuster^[105] have been credited with the demonstration of increased epidermal replacement after they found an increase in the uptake of amino acids by the PRP lesions. Later on, several *in vivo* and *in vitro* autoradiography studies using titrated thymidine confirmed




Figure 3: Adult onset pityriasis rubra pilaris: Type I classical adult, sections prepared from the biopsy of a papule (nonfollicular) depicting orthokeratosis, alternating parakeratosis, thick suprapapillary plate, short and broad rete-ridges and a mild nonspecific inflammatory infiltrate (H and E, X100)




Figure 4: Adult onset pityriasis rubra pilaris: Type II atypical adult-sections prepared from the biopsy of a papule (follicular) showing in addition, keratotic plugging-an exquisite feature of the condition (H and E, X400)

an increase in the labeling index of PRP epidermal cells when compared with normal, reflecting increased cell proliferation.^[42,49,50,51,53,106] Electron microscopy revealed a decrease in the number of tonofilaments, desmosomes, and enlarged intercellular spaces.^[49,107] The corneocytes are fusiform and show numerous pits.^[107] Evidence of parakeratosis of the stratum corneum is seen as lipid-like vacuoles, incomplete keratinization, and remnants of nuclei.^[58,107]

LABORATORY FINDINGS

Hematological and laboratory test results are usually

within normal limits; the main emphasis remains on the histopathology. Plasma vitamin A and carotenoid levels are normal,^[62-64] although retinal-binding protein may be

low^[54] or normal.^[55-58] Direct immunofluorescence tests with antibodies to human IgG, IgM, IgA and complement C₃ were found to be negative in 15 adult PRP patients by Niemi

Table 3: Treatment options in adult onset pityriasis rubra pilaris

Treatments of historical importance					
Author(s)	Years	Recommended drug(s)	Dosage	Response / Result	Number of patients
Petter ^[131] , Gunther ^[132] , Gunther S, Alston W ^[133] , Randle, Diaz-Perez, Winkelmann ^[134] , Winkelmann, Thomas, Randle ^[135] , Kellum ^[136] Murray, Gilgor, Lazarus ^[137] Anonymous ^[143]	1936, 1983, 1971	Vitamin A	1,000,000 IU/per day x/2 weeks	Good	2
Ayres, Mihan, Scribner ^[138]	1979	Vitamins A and E	500,000 IU + 200-400 IU	Synergism of vitamins A and E	A report
Skinner, Rosenberg,	1981	Cod liver oil	1-3 mL/day	Worthwhile	Case report / letter
Pucevich, Kaplan ^[140]					
Brunsting Sheard ^[141]	1941	Habibul liver oil	1-3 mL/day	Good	-
Weiner, Levin ^[142]	1943	Carotene	-	Good in some cases only	-
Webster and Falk ^[175]	1952	ACTH +Vitamin A	1,000,000 IU of Vitamin A + 10-20 units Adreno cortico trophic hormone/week	Favorable	2 patients
Irgang ^[178]	1968	Ascorbic acid	Oral and I/M 500 mg to 1 gm	Useful in isolated cases	-
Watt and Jilson ^[179]	1965	Pencillin and antitubercular drugs	Penicillin V 1 g/day plus usual anti tubercular regimen	Equivocal	6 patients
Modern treatments for adult onset PRP					
Kirby, Watson R ^[156] , Herbst Vogelbruch, Ehnis, Kiehl, Kapp, Weiss ^[157]	2000 2000	Retinoid +UV light	Acetretrin + UVA: 1 (0.75 mg/kg/day) acetretin + narrowband UV-B (Re-TL-01)	Favorable Favorable	Case report/ letter A case report / letter
Hofer, Mullegger, Kerl, Wolf ^[158] Neess, Hinrichs, Dissemond, Herrmann, Poswig, Servera-Llanras <i>et al</i> ^[161]	1999 2000	PUVA	Extracorporeal photo-chemotherapy	Mild to moderate good in erythroderma	Case report/ letter 1
Lamar and Gaethe ^[162]	1964	Methotrexate	5-30 mg/week	Equivocal good to mild	-
Duncan, Imaeda, Milstone ^[168]	1998			Good	Case report/ review
Ahmed and Moy ^[169]	1981	Azothioprine	50-200 mg/day		Review
Gendler ^[171]	1984				
Rosenbach and Lowe ^[172]	1993	Cyclosporine	< 5 mg/kg/day	Good in recalcitrant PRP	Case report/letter case report
Meyer and van Voorst Vader ^[174]	1989				
Lim and Tham ^[41]	1991	Systemic prednisolone	20-60 mg/day	Useful only in some cases	4
Brice, Spencer ^[55]	1985	Stanozolol	2 mg/day	Good result in some cases	Letter case report
Pavlidakey, Hashimoto, Savoy, Heller, Iacobelli, Barfield ^[180]	1985				
van de kerkhof and de Jong ^[181] Thiers ^[183]	1991 1997	Calcipotriol	Topical ointment applied daily	Same cases may respond	Case report/ letter
Coras, Vogt, Ulrich, Landthaler, Hohenleutner, ^[184]	2005	Fumaric acid	*Recommended dosages	Claimed to be useful	-
Haenssle, Bertsch, Emmert, Wolf, Zutt ^[185]	2004	Extracorporeal photo- chemotherapy (ECP)	2 Joule/cm ² , monthly interval on 2 consecutive days	Good results in isolated cases	-

et al.^[42] However, immunoelectrophoresis of the scales from PRP demonstrated the presence of only IgG, while psoriatic scales had IgG, IgA and C₃.^[108] Takematsu *et al.*^[109,110] recorded normal levels of leukotriene B₄ but low levels of anaphylotoxins in scale extracts from PRP. Other studies have been done on HLA typing,^[42] direct immunofluorescence,^[42] keratin monoclonal antibodies,^[15] parathyroid hormone levels,^[111] and a western blot analysis of the skin,^[15] but these studies only have academic significance.

DIAGNOSIS

Until the disease is well-developed, it may be difficult to diagnose with full confidence. However, repeated observations and a few biopsies may confirm the diagnosis.^[2-4,24,112-116] Atypical (type II) PRP may be more difficult to diagnose than classical adult onset (type I) PRP. Follicular hyperkeratosis on the back of the fingers, orange-colored eruptions with intervening areas of normal skin 'islands of sparing' and/or palmoplantar keratoderma are features of classical adult onset PRP; they are ill defined in atypical adult PRP.^[2-4,117] The differential diagnosis of adult onset PRP usually includes psoriasis.^[2,4,118] The absence of Auspitz and candle grease signs is an instant clinical diagnostic clue.^[2,3] Erythrodermic PRP can be confused with other forms of erythroderma^[119] and skin biopsy of such patients can confirm PRP only on an exclusion basis.^[101] Arthropathic PRP is unusual to record.^[120] Resolving PRP may mimic seborrhoeic dermatitis^[2] or erythema gyratum repens.^[17,121] PRP may be a cutaneous marker of internal malignancy,^[92,93,95,122] leukemia,^[93] metastatic carcinoma,^[92] or Sezary syndrome^[123] in adults, which may follow after a variable length of time. Interestingly, cutaneous T-cell lymphoma and Sezary's syndrome also form a differential diagnosis of erythrodermic PRP.^[124,125] Rarely, dermatomyositis may develop skin eruptions akin to the adult onset PRP.^[126-130] Heteroduplex analysis of T-cell receptor gamma gene arrangements may be a newer adjuvant diagnostic tool in skin biopsies from erythrodermas.^[128]

TREATMENT OPTIONS

The diagnosis and treatment of PRP have always been a source of great interest. There is no acclaimed treatment for PRP at present. Thus, affected individuals often visit and change many treating dermatologists to alleviate their signs and symptoms. More often than not, it is an exercise in futility as the treating physician/dermatologist too is in dilemma. Several treatment^[131-191] options have been *in vogue* and are tabulated below [Table 3].

Narrowband UV-B with oral retinoids has been useful in some cases.^[182,187] Topical calcipotriol^[138] and tacalcitol have also given promising results in some patients. HIV-associated PRP is more recalcitrant but antiretroviral drug therapy has caused alleviation of the symptoms and may even cause complete regression in such patients.^[188] Methotrexate has been found to be moderately effective. In an attempt to explore an ideal therapy, newer treatment options like biologicals (infliximab), calcineurin inhibitors (pimecrolimus) etc. are being tried in PRP.^[192,193] The use of emollients to symptomatically improve the condition may also be useful. It is imperative to record at this point in time, that several treatment options that have been used so far may not be satisfactory as no organized drug trials are available. Nevertheless, isotretinoin, a retinoid, seems to be a plausible option.^[149,154,189-191]

The historical and epidemiological perspectives of adult onset PRP as well as its etiology have been described. Microscopic pathology and its variations have been clearly defined, emphasizing its role in supplementing clinical diagnosis and treatment has been facilitated by the inclusion of a table for decision-making.

REFERENCES

1. Tarral C. General psoriasis-desquamation from the parts covered by hair. In: Rayer P, editor. A theoretical and practical treatise on the diseases of the skin. 2nd ed, London: Baillere; 1835. p. 648-9.
2. Griffiths WA, Judge MR, Leigh IM. Disorders of keratinization-pityriasis rubra Pilaris. In: Champion RH, Burton JL, Burns DA, *et al*, editors. Text Book of dermatology, 6th ed. London: Blackwell Science; 1988. p. 1539-45.
3. Gold Smith LA, Baden HP. Pityriasis rubra pilaris. In: Freeberg IM, Eisen AZ, Wolff K, *et al*, editors. Dermatology in general medicine. Vol 1 6th ed. London: Mc-Graw Hill Publication; 2003. p. 442-4.
4. Albert MR, Mackool BT. Pityriasis rubra pilaris. Int J Dermatol 1999;38:1-11.
5. White KL. Pityriasis rubra pilaris. Dermatol Online J 2003;9:6.
6. Vijayalakshmi AM, Malika A. Pityriasis rubra pilaris. Indian Pediatr 2003;40:432-3.
7. Selvaag E, Haederstel M, Thomsen K. Pityriasis rubra pilaris: A retrospective study of 12 patients. J Eur Acad Dermatol Venerol 2000;14:514-5.
8. Sehgal VN, Bajaj P, Jain S. Pityriasis rubra pilaris -report of four cases. J Dermatol 2000;27:174-7.
9. Sorensen KB, Thestrup-Pedersen K. Pityriasis rubra pilaris: A retrospective analysis of 43 patients. Acta Derm Venereol 1999;79:405-6.
10. Varma S, Logan RA. Exanthematic pityriasis rubra pilaris. Br J Dermatol 1999;141:769-71.

11. Clayton BD, Jorizzo JL, Hitchcock MG, Fleischer AB Jr, Williford PM, Feldman SR, *et al.* Adult pityriasis rubra pilaris: A 10 year case series. *J Am Acad Dermatol* 1997;36:959-64.
12. Cecchi R, Giomi A, Tuci F, Bartoli L, Seghieri G. Pityriasis rubra pilaris, lichen planus, alopecia universals and vitiligo in a single patients with chronic viral hepatitis C. *Dermatology* 1994;188:239-40.
13. Griffiths A. Pityriasis rubra pilaris - Etiologic considerations. *J Am Acad Dermatol* 1984;10:1086-8.
14. Sehgal VN, Jain S, Kumar S, Bhattacharya SN, Sardana K, Bajaj P. Familial pityriasis rubra pilaris (Adult classic - I): A reports of 3 cases in a single family. *Skinmed Dermatol clin* 2002;1:161-4.
15. Vanderhooft SL, Francis JS, Holbrook KA, Dale BA, Fleckman P. Familial pityriasis rubra pilaris. *Arch Dermatol* 1995;131:448-53.
16. Holden CA, Curley RK. Down's syndrome and pityriasis rubra pilaris. *Clin Exp Dermatol* 1989;14:332.
17. Hazini AR, Rongioletti F, Rebora A. Pityriasis rubra pilaris and vitiligo in Down's syndrome. *Clin Exp Dermatol* 1988;13:334-5.
18. Bonomo RA, Korman N, Nagashima-Whalen L Briggs J, Graham R, Salata RA. Pityriasis rubra pilaris: An unusual cutaneous complication of AIDS. *Am J Med Sci* 1997;314:118-21.
19. Misery I, Faure M, Claidy A. Pityriasis rubra pilaris and HIV infection- type 6 pityriasis rubra pilaris. *Br J Dermatol* 1996;135:1008-9.
20. Miralles ES, Nunez M, De Las Heras ME, Perez B, Moreno R, Ledo A. Pityriasis rubra pilaris and HIV infection. *Br J Dermatol* 1995;133:990-3.
21. Resnick SD, Murrel DF, Woosley JT. Pityriasis rubra pilaris, acne conglobata, and elongated follicular spines: An HIV associated follicular syndrome. *J Am Acad Dermatol* 1993;29:283.
22. Blauvelt A, Nahass GT, Pardo RJ, Kerdel FA. Pityriasis rubra pilaris and HIV infection. *J Am Acad Dermatol* 1991;24:703-5.
23. Sehgal VN, Srivastava G. (Juvenile) pityriasis rubra pilaris. *Int J Dermatol* 2006;45:438-46.
24. Devergie A. *Traité pratique des maladies de la peau.* (In French) Paris: Masson; 1857. p. 454-64.
25. Besnier E. *Observation pour servir a historic clinique du, pityriasis rubra pilaris* (In French). *Am Dermatol Syphil (Paris)* 1889;10:253-87.
26. Bergeron JR, Stone OJ. Follicular occlusion triad in a follicular blocking disease (pityriasis rubra pilaris). *Dermatologica* 1968;136:362-7.
27. Davidson CL Jr, Winkelman RK, Kierland RR. Pityriasis rubra pilaris: A follow up study of 57 patients. *Arch Dermatol* 1969;100:175-8.
28. Kint A, De Bie S, Geerts ML, T'Kint R. Pityriasis rubra pilaris: A familial condition. *Arch Belg Dermatol Syphiligr* 1972;28:371-6.
29. Binnick SA. Pityriasis rubra pilaris. *Int J Dermatol* 1979;18:587-8.
30. Fox BJ, Odom RB. Papulo - squamous disease: A review. *J Am Acad Dermatol* 1985;12:597-624.
31. Sehgal VN, Jain MK, Mathur RP. Pityriasis rubra pilaris in Indians. *Br J Dermatol* 1989;121:821-2.
32. Griffiths WA. Pityriasis rubra pilaris: A historical approach. *Trans St Johns Hosp Dermatol Soc* 1975;61:58-69.
33. Griffiths WA. Pityriasis rubra pilaris: An historical approach 2, Clinical features. *Clin Exp Dermatol* 1976;1:37-50.
34. Griffiths WA. Pityriasis rubra Pilaris. *Clin Exp Dermatol* 1980;5:105-12.
35. Gelmetti C, Cerri D. Pityriasis rubra pilaris-the problems of its classification. *J Am Acad Dermatol* 1990;23:1186-8.
36. Griffiths WA. Pityriasis rubra pilaris-the problems of its classification. *J Am Acad Dermtol* 1992;26:140-2.
37. Piamphongsant T, Akaraphant R. Pityriasis rubra pilaris: A new proposed classification. *Clin Exp Dermtol* 1994;19:134-8.
38. Martin AG, Weaver CC, Cockerell CJ, Bergcr TG. Pityriasis rubra pilaris in the setting of HIV infection: Clinical behavior and association with explosive cystic acne. *Br J Dermatol* 1992;126:617-20.
39. Sanchez-Regana M, Fuentes CG, Creus L, Salleras M, Umbert P. Pityriasis rubra pilaris and HIV infection: A part of the spectrum of HIV-associated follicular syndrome. *Br J Dermatol* 1996;135:1008-9.
40. Gonzalez-Lopez A, Velasco E, Pozo T, Del Villar A. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. *Br J Dermatol* 1999;140:931-4.
41. Lim JT, Tham SN. Pityriasis rubra pilaris in Singapore. *Clin Exp Dermatol* 1991;16:181-4.
42. Niemi KM, Kousa M, Storgards K, Karvonen J. Pityriasis rubra pilaris: A clinico- pathological study with a special reference to autoradiography and histocompatibility antigens. *Dermatologica* 1976;152:109-18.
43. Magro CM, Crowson AN. The clinical and histomorphological features of pityriasis rubra pilaris: A comparative analysis with psoriasis. *J Cutan Pathol* 1997;24:416-24.
44. Jacky WK. Pityriasis rubra Pilaris in Black South Africans. *Clin Exp Dermatol* 1999;24:160-3.
45. Gelmeti C, Schiuma AA, Cerri D, Gianotti F. Pityriasis rubra pilaris in childhood: A long term study of 29 cases. *Pediatr Dermatol* 1986;3:446-51.
46. Betjkmann DB, Bith, Heuyer. Pityriasis rubra pilaris familial. *Am Dermatol Syphiligr (Paris)* 1910;1:609-19.
47. Wells RS. In Discussion on Borrie P. Pityriasis rubra pilaris treated with Methotrexate. *Br J Dermatol* 1967;79:115-6
48. Knudsen EA. Pityriasis rubra pilaris in identical twins. *Br J Dermatol* 1958;70:27-9
49. Braun-Falco O, Ryckmanns F, Schmoeckel C, Landthaler M. Pityriasis rubra pilaris: A clinico pathological and therapeutic study with special reference to histochemistry, radiography and electron microscopy. *Arch Dermatol Res* 1983;275:287-95.
50. Harper RA, Rispflf J. Pityriasis rubra pilaris epidermal cell *in vitro*: A comparison with normal and psoriatic cells. *Arch Dermatol Res* 1977;260:253-5.
51. Ralfs IG, Dawber RP, Ryan TJ, Wright NA. Pityriasis rubra pilaris-epidermal cell kinetics *Br J Dermatol* 1981;104:249-52.
52. Kanitakis J, Hoyo E, Chouvet B, Thivolet J, Faure M, Claudy A. Keratinocyte proliferation in epidermal keratinocyte

- disorders evaluated through PCNA/ Cyclin immunolabelling and AGNOR counting. *Acta Derm Venereol* 1993;73:370-5.
53. Griffiths WA, Pieris S. Pityriasis rubra pilaris: An autoradiographic study. *Br J Dermatol* 1982;107:665-7.
 54. Finzi AF, Altomare G, Bergamaschini L, Tucci A. Pityriasis rubra pilaris and retinol binding protein. *Br J Dermatol* 1981;104:253-6.
 55. Brice SL, Spencer SK. Stanozolol in the treatment of pityriasis rubra pilaris. *Arch Dermatol* 1985;121:1105-6.
 56. Van Voorst Vader PC, Van Oostveen F, Houthoff HJ, Marrink J. Pityriasis rubra pilaris, Vitamin A and Retinol binding protein: A case study. *Acta Derm Venereol* 1984;64:430-2.
 57. Stoll DM, King LE Jr, Chytil F. Serum levels of retinol binding protein in patients with pityriasis rubra pilaris. *Br J Dermatol* 1983;108:375.
 58. Kanerva L, Lauharanta J, Niemi KM, Lassus A. Ultrastructure of pityriasis rubra pilaris with observation during retinoid treatment. *Br J Dermatol* 1983;108:653-63.
 59. Frazier CN, Hu CK. Cutaneous lesions associated with a deficiency of vitamin A in man. *Arch Intern Med*. 1931;48:507-14.
 60. Frazier CN., Hu CK. Nature and distribution according to age of cutaneous manifestation of vitamin A deficiency: A study of 207 cases. *Arch Dermatol Syphilol* 1936;33:825-52.
 61. Lowenthal LJ. A new cutaneous manifestation in the syndrome of vitamin A deficiency. *Arch Dermatol Syphilol* 1933;28:700-8.
 62. Cornbleet T. Liver Vitamin A in Darier's and Davergies disease. *J Invest Dermatol* 1954;23:71-3.
 63. Gross DA, Landay JW, Newcomer VD. Pityriasis rubra pilaris-report of a case and analysis of the literature. *Arch Dermatol* 1969;99:710-6.
 64. Griffiths WA. Vitamin A and pityriasis rubra pilaris. *J Am Acad Dermatol* 1982;7:555.
 65. Mier PD, Van Den Hurk J, Van Rossen E. Plasma vitamin A levels in dyskeratosis. *Br J Dermatol* 1975;92:73-5.
 66. Rothman S. Physiology and biochemistry of the skin. Chicago: University of Chicago Press; 1954. p. 382-90.
 67. Skov L, Baadsgaard O. Superantigens: Do they have a role in skin diseases? *Arch Dermatol* 1995;131:829-32.
 68. Yamamoto T, Yokoyama A. Lymphocyte response to superantigen in a patient with childhood-onset pityriasis rubra pilaris. *Int J Dermatol* 1999;38:639-40.
 69. Betloch I, Ramon R, Silvestre JF, Carnero L, Albares MP, Banuls J. Acute juvenile pityriasis rubra pilaris: A superantigen mediated disease? *Pediatr Dermatol* 2001;18:411-4.
 70. Barr RJ, Young EM Jr. Psoriasisiform and Papulosquamous disorders. *J Cutan Pathol* 1985;12:412-25.
 71. Mohrenschlager M, Abeck D. Further clinical evidence for involvement of bacterial superantigens in juvenile pityriasis rubra pilaris (PRP): Report of two new cases. *Pediatr Dermatol* 2002;19:569.
 72. Shahidullah H, Aldridge RD. Changing forms of Juvenile pityriasis rubra pilaris. *Clin Exp Dermatol* 1994;19:254-6.
 73. Pankajan R, Vinod Kumar CH, Rajendran V, Ramesh K, Anandadasan PK, Bhatia VN, *et al.* Pityriasis rubra pillars with leprophobia. *Int J Lepro Other Micobact Dis* 1987;55:555-6.
 74. Koehn GG. Dermanatic follicular plugging in pityriasis rubra pilaris. *J Am Acad Dermatol* 1990;23:526-7.
 75. Castanet J, Lacour JP, Perrin C, Brun P, Ortonne JP. Juvenile pityriasis rubra pilaris associated with hypogammaglobulinaemia and furunculosis. *Br J Dermatol* 1994;131:717-9.
 76. Selvaag E, Haedersdal M, Thomsen K. Pityriasis rubra pilaris: A retrospective study of 12 patients. *J Eur Acad Dermatol Venereol* 2000;14:514-5.
 77. Mortimer PS, Dawber RP. Dermatologic disease of the nail unit other than psoriasis and lichen planes. *Dermatol Clin* 1985;3:401-7.
 78. Sonnex TS, Dawber RP, Zachary CB, Millard PR, Griffiths AD. The nails in adult type I pityriasis rubra pilaris: A comparison with psoriasis and sezary syndrome and psoriasis. *J Am Acad Dermatol* 1986;15:956-60.
 79. Lambert DG, Dalac S. Nail changes in type 5 Pityriasis rubra Pilaris. *J Am Acad Dermatol* 1989;21:811-2.
 80. Baden HP, Roth SI. Oral Lesions in pityriasis rubra pilaris. *Oral Surg Oral Med Oral Pathol* 1968;25:691-4.
 81. Boyd AS, Zemtsov A, Neldner KH. Pityriasis rubra pilaris presenting as subacute cutaneous lupus erythematosus. *Cutis* 1993;52:177-9.
 82. Tunnessen WW Jr, Nieburg PI, Voorhess ML. Hypothyroidism and pityriasis rubra pilaris: Response to thyroid hormone. *J Pediatr* 1976;88:456-8.
 83. Aguilar AR, Gomez F, Balsa FT, Framil JP, Oubina PN. Pityriasis rubra pilaris with muscle and joint involvement. *Dermatologica* 1973;146:361-6.
 84. Randle HW, Winkelmann RK. Pityriasis rubra pilaris and celiac sprue with malabsorption. *Cutis* 1980;25:626-7.
 85. Cohen PR, Prystowsky JH. Pityriasis rubra pilaris: A review of diagnosis and treatment. *J Am Acad Dermatol* 1989;20:801-7.
 86. Ng SK, Ang CB, Tham A. Kaposi's varicelliform eruption in a patient with pityriasis rubra pilaris. *J Am Acad Dermatol* 1992;27:263.
 87. Lister RK, Perry JD, Cerio R. Pityriasis Rubra Pilaris and seronegative polyarthritis. *Br J Dermatol* 1997;137:318-9.
 88. Conaghan PG, Sommer S, McGonagle D, Veale D, Waldmann H, Hale G *et al.* The relationship between pityriasis rubra Pilaris and inflammatory arthritis: Case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. *Arthritis Rheum* 1999;42:1998-2001.
 89. Behr FD, Bangert JL, Hansen RC. Atypical pityriasis rubra pilaris associated with arthropathy and osteoporosis: a case report with 15-year follow-up. *Pediatr Dermatol* 2002;19:46-51.
 90. Nakafusa J, Misago N, Narisawa Y. Pityriasis rubra pilaris in association with polyarthritis. *Dermatology* 2002;205:298-300.
 91. Waldorf DS, Hambrick GW Jr. Vitamin-A responsive pityriasis rubra pilaris with myasthenia gravis. *Arch Dermatol* 1965;92:424-7.
 92. Sanchez-Regana M, Lopez-Gil F, Salleras M, Umberto P. Pityriasis rubra pilaris as the initial manifestation of internal neoplasia. *Clin Exp Dermatol* 1995;20:436-8.
 93. Reinhardt LA, Rosen T. Pityriasis rubra pilaris as initial

- manifestation of leukemia. *Cutis* 1983;31:100-2.
94. Tannenbaum CB, Billick RC, Srolovitz H. Multiple cutaneous malignancies in a patient with pityriasis rubra pilaris and focal acantholytic dyskeratosis. *J Am Acad Dermatol* 1996;35:781-2.
 95. Huynh NT, Hunt MJ, Cachia AR, Veness MJ. Merkel cell carcinomas and multiple cutaneous squamous cell carcinomas in a patient with pityriasis rubra pilaris. *Australas J Dermatol* 2002;43:48-51.
 96. Schwengle LE, Rampen FH. Eruptive seborrheic keratoses associated with erythrodermic pityriasis rubra pilaris: Possible role of retinoid therapy. *Acta Dermatol Venereol* 1988;68:443-5.
 97. Kaskel P, Peter RU, Kerscher M. Phototesting a phototherapy in pityriasis rubra pilaris. *Br J Dermatol* 2001;144:430.
 98. Yaniv R, Barzilai A, Trau H. Pityriasis rubra pilaris is exacerbated by UV-B phototherapy. *Dermatology* 1994;189:313.
 99. Marguery MC, Durand-Malgouyres C, Bayle-Lebey P, Dupin P, Bazex J. Photosensitive and phototriggered: Pityriasis Rubra Pilaris. *Photodermatol Photoimmunol Photomed* 1994;10:42-5.
 100. Lever WF, Schaumburg Lever G. Pityriasis Rubra Pilaris. In: Lever WF, Schaumburg Lever G. *Histopathology of the skin*. 7th ed. Philadelphia: J.B Lipponcott; 1996. p. 176-8.
 101. Walsh NM, Prokopetz R, Tron VA, Sawyer DM, Watters AK, Murray S, *et al.* Histopathology in erythroderma - review of a series of cases by multiple observers. *J Cutan Pathol* 1994;21:419-23.
 102. Cowen P, O'Keefe R. Pityriasis rubra pilaris and focal acantholytic dyskeratosis. *Australas J Dermatol* 1997;38:40-1.
 103. Howe K, Foresman P, Griffin T, Johnson W. Pityriasis rubra pilaris with acantholysis. *J Cutan Pathol* 1996;23:270-4.
 104. Duke RA, Barrett MR, Salazer JE, Scott RL, Sebes JE. Acro-osteolysis secondary to Pityriasis rubra pilaris. *AJR Am J Roentgenol* 1987;149:1082-3.
 105. Porter D, Shuster S. Epidermal renewal and amino acids in psoriasis and pityriasis rubra pilaris. *Arch Dermatol* 1968;98:339-43.
 106. Marks R, Griffiths A. The epidermis in Pityriasis rubra pilaris: A comparison with psoriasis. *Br J Dermatol* 1973;89:19-20.
 107. Amer M, Mostafa FF, Tosson Z, Nasr AN. Corneocytes in scaly parakeratotic disease. *Int J Dermatol* 1996;35:417-21.
 108. Kaneko F, Muramatsu R, Takahashi Y, Miura Y. Extractable immune complex in soluble substance from psoriatic scale. *Arch Dermatol Res* 1984;276:45-51.
 109. Takematsu H, Teruni T, Tagami H. Demonstration of leukotriene B₄ in the scale extracts of psoriasis and inflammatory pustular dermatoses: Correlation with leukocyte chemotactic activity and C5a anaphylatoxin. *Acta Dermato-Venereol (Stockh)* 1986;66:6-10.
 110. Takematsu H, Ohkouchi K, Tagami H. Demonstration of Anaphylatoxins C3(a), C4(a) C5(a) in the scale of psoriasis and inflammatory pustular dermatoses. *Br J Dermatol* 1986;114:1-6.
 111. Milstone LM, Ellison AF, Insogna KL. Serum parathyroid hormone level is elevated in some patients with disorders of keratinization. *Arch Dermatol* 1992;128:926-30.
 112. Westerhof W, Dingemans KP. The morphology of keratohyalin granules in orthokeratotic and parakeratotic skin and oral mucosa. *Int J Dermatol* 1987;26:308-13.
 113. Kao GF, Sulica VI. Focal acantholytic dyskeratosis occurring in pityriasis rubra pilaris. *Am J Dermatopathol* 1989;11:172-6.
 114. Kariniemi AL, Virtanen I. Altered Keratin expression in benign malignant skin disease revealed with monoclonal Antibodies. *Am J Dermatopathol* 1989;11:202-8.
 115. Gandarillas A, Goldsmith LA, Gschmeissner S, Leigh, I.M, Watt, FM. Evidence that apoptosis and terminal differentiation of epidermal keratinocytes are distinct process. *J Exp Dermatol* 1999;8:71-9.
 116. Hashimoto K, Fedoronko L. Pityriasis rubra pilaris with acantholysis and lichenoid histology. *Am J Dermatopathol* 1999;21:491-3.
 117. Caplan SE, Lowitt MH, Kao GF. Early presentation of pityriasis rubra pilaris. *Cutis* 1997;60:291-6.
 118. Belew-Noah PW, Rosenberg WE, Zabriskie JB, Skinner RB Jr, Henson TH, Beard GB. Microbial association and response to antimicrobial seen in a psoriasis clinic. *Adv Exp Med Biol* 1997;418:157-9.
 119. Sehgal VN, Srivastava G. Exfoliative dermatitis's: A prospective study of 80 patients. *Dermatologica* 1986;173:278-84.
 120. Fiallo P, Tagliapietra AG, Santoro G. Arthropathic pityriasis rubra pilaris. *Br J Dermatol* 1996;134:1154-5.
 121. Cheesbrough MJ, Williamson DM. Erythema gyratum repens: A stage in the resolution of pityriasis rubra pilaris? *Clin Exp Dermatol* 1985;10:466-71.
 122. Sharma S, Weiss GR, Paulger B. Pityriasis rubra pilaris as a initial presentation of hepatocellular carcinoma. *Dermatology* 1997;194:166-7.
 123. Roger J, Burg G, Miller K, Lanz U. Pityriasis rubra pilaris-artiges Vorstadium eines Sézary-Syndroms (Pityriasis rubra pilaris the precursor of a Sézary's syndrome). *Z Hautkr* 1991;66:1046-50.
 124. Westfried M, Rosenthal JC, Coppola A, Rapp Y. Sezery syndrome presenting as follicular dermatosis. *Cutis* 1982;29:390-6.
 125. Schmoeckel C, Burg G, Hoffmann-Fezer G, Stolz W, Weitz H, Löhns U, *et al.* Cutaneous immunoblastic T-cell Lymphoma. *Arch Dermatol Res* 1982;274:141-54.
 126. Lupton JR, Figueroa P, Berberian BJ, Sulica VI. An Unusual presentation of Dermatomyositis - the type wong variant revisited. *J Am Acad Dermatol* 2000;43:908-12.
 127. Requena L, Grilli R, Soriano L, Escalonilla P, Farina C, Martin L. Dermatomyositis with a pityriasis rubra pilaris-like eruption: A little-known distinctive cutaneous manifestation of dermatomyositis. *Br J Dermatol* 1997;136:768-71.
 128. Cherny S, Mraz S, Su L, Harvell, J, Kohler S. Heteroduplex analysis of T-cell receptor γ gene rearrangement as an adjuvant diagnostic tool in skin biopsies for erythroderma. *J Cut Am Pathol* 2001;28:351-5.
 129. Dicken CH. Treatment of classic Pityriasis rubra pilaris. *J Am Acad Dermatol* 1994;31:997-9.
 130. Shackelford KE, Belsito DV. The etiology of allergic-appearing

- foot dermatitis: A 5 year retrospective study. *J Am Acad Dermatol* 2002;47:715-21.
131. Petter MF. Pityriasis Rubra Pilaris, with particular reference to vitamin medication and dietary control. *Penn Med J* 1936;39:864-6.
 132. Gunther S. Topical administration of vitamin A acid (retinoic acid) in palmar keratoses: Callosities, hyperkeratotic eczema, hypertrophic lichen planus, pityriasis rubra pilaris. *Dermatologica* 1972;145:344-7.
 133. Gunther S, Alston W. follicular keratosis. Pilot slides of serum levels of vitamin A, and LFT during administration of retinoic acid in kyle's diseases, Pityriasis Rubra Pilaris and Darier's disease. *Dermatologica* 1973;147:274-83.
 134. Randle HW, Diaz-Perez JL, Winkelmann RK. Toxic doses of vitamin A for pityriasis rubra pilaris. *Arch Dermatol* 1980;116:888-92.
 135. Winkelmann RK, Thomas JR 3rd, Randle HW. Further experience with toxic Vitamin A therapy in Pityriasis Rubra Pilaris. *Cutis* 1983;31:621-32.
 136. Kellum RE. Possible significance of aqueous emulsified Vitamin A in effective therapy for pityriasis rubra pilaris. *J Am Acad Dermatol* 1989;20:126-8.
 137. Murray JC, Gilgor RS, Lazarus GS. Serum triglyceride elevation following high dose Vitamin A treatment for pityriasis rubra pilaris. *Arch Dermatol* 1983;119:675-6.
 138. Ayres S, Jr, Mihan R, Scribner MD. Synergism of Vitamin A and E with dermatologic application. *Cutis* 1979;23:600-3.
 139. Ayres S Jr. Pityriasis Rubra Pilaris controlled by synergism of Vitamin A and E. *J Am Acad Dermatol* 1981;5:350-1.
 140. Skinner RB Jr, Rosenberg EW, Pucevich MV, Kaplan RJ. Cod liver oil and skin disease. *J Am Acad Dermatol* 1981;5:222.
 141. Brunsting LA, Sheard C. Dark adaptation in pityriasis rubra pilaris. *Arch Dermatol Syphilol* 1941;43:42-61.
 142. Weiner AL, Levin AA. Pityriasis rubra pilaris of familial type -experience in therapy with carotene and vitamin A. *Arch Dermatol Syphilol* 1943;48:288-96.
 143. Anonymous. Clinical trials with topical Vitamin A acid. *South Med J* 1971;64:1496-502.
 144. Happle R, van de Kerkhof PC, Traupe H. Retinoids in disorders of keratinization: Their use in adults. *Dermatologica* 1987;175:107-24.
 145. Borok M, Lowe NJ. Pityriasis rubra pilaris: Further observation of systemic retinoid therapy. *J Am Acad Dermatol* 1990;22:792-5.
 146. van-Dooren-Greebe RJ, van-de-kerkhof PC. Extensive extraspinal hyperostosis after long term oral retinoid treatment in a patient of pityriasis rubra pilaris. *J Am Acad Dermatol* 1995;32:322-5.
 147. Blanchet-Bardon C, Nazzaro V, Rognin C, Geiger JM, Puissant A. Acitretin in the treatment of severe disorders of keratinization: Results of an open study. *J Am Acad Dermatol* 1991;24:982-6.
 148. Basta Juzbasic A, Dobric I, Schonwald D. Acitretin in the treatment of pityriasis rubra pilaris. *Retinoids, Today Tomorrow* 1994;35:7-10.
 149. Peck GL, Yoder FW, Olsen TG, Pandya MD, Butkus D. Treatment of Darier's Disease, lamellar ichthyosis: Pityriasis rubra pilaris, cystic acne and basal cell carcinoma with oral 13cis retinoic acid. *Dermatologica* 1978;157:11-2.
 150. Gilgor RS, Chiaramonti A, Goldsmith LA, Lazarus GS. Evaluation of 13-cis retinoic acid in lamellar ichthyosis, pityriasis rubra pilaris and Darier's diseases. *Cutis* 1980;25:380-5.
 151. Farb RM, Lazarus GS, Chiaramonti A, Goldsmith LA, Gilgor RS, Balakrishnan CV. The effect of 13-Cis retinoic acid on epidermal lysosomal hydrolase activity in Darier's diseases and Pityriasis Rubra Pilaris. *J Invest Dermatol* 1980;75:33-5.
 152. Goldsmith LA, Weinirich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis retinoic acid (Isotretinoin). *J Am Acad Dermatol* 1982;6:710-5.
 153. Becker K. Isotritinoin: A review. *Ariz Med* 1983;40:88-90.
 154. Dicken CH. Isotretinoin treatment of pityriasis rubra pilaris. *J Am Acad Dermatol* 1987;16:297-301.
 155. Fleissner J, Happle R. Etreinate in the treatment of Juvenile pityriasis rubra pilaris. *Arch Dermatol* 1981;117:749-50.
 156. Kirby B, Watson R. Pityriasis rubra pilaris treatment with acitretin and narrow band ultraviolet B (Re-TL-01). *Br J Dermatol* 2000;142:376-7.
 157. Herbst RA, Vogelbruch M, Ehnis A, Kiehl P, Kapp A, Weiss J. Combined UV A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. *Br J Dermatol* 2000;142:574-5.
 158. Hofer A, Mullegger R, Kerl H, Wolf P. Extracorporeal photo chemotherapy for the treatment of erythrodermic pityriasis rubra pilaris. *Arch Dermatol* 1999;135:475-6.
 159. Kaskel P, Grundmann-Kollmann M, Schiller PI, Krahn G, Pillekamp H, Peter RU, *et al.* Bath PUVA as a treatment for pityriasis rubra pilaris provoked by ultraviolet B. *Br J Dermatol* 1999;140:769-70.
 160. Khoo L, Asawanonda P, Grevelink SA, Taylor CR. Narrow band UVB- associated lesional blisters in pityriasis rubra pilaris. *J Am Acad Dermatol* 1999;41:803-4.
 161. Neess CM, Hinrichs R, Dissemmond J, Herrmann G, Poswig A, Servera-Llanras M *et al.* Treatment of pruritus by capsaicin in a patient with Pityriasis Rubra Pilaris receiving RE-PUVA therapy. *Clin Exp Dermatol* 2000;25:209-11.
 162. Lamar LM, Gaethe G. Pityriasis rubra pilaris. *Arch Dermatol* 1964;89:515-22.
 163. Anderson FE. Pityriasis rubra pilaris treated with methotrexate. *Australas J Dermatol* 1966;8:183-5.
 164. Brown J, Perry HO. Pityriasis rubra pilaris- treatment with folic acid antagonists. *Arch Dermatol* 1966;94:636-8.
 165. Parish LC, Woo TH. Pityriasis rubra pilaris in Korea- treatment with methotrexate. *Dermatologica* 1969;139:399-403.
 166. Knowles WR, Chernosky ME. Pityriasis rubra pilaris - prolonged treatment with methotrexate. *Arch Dermatol* 1970;102:603-12.
 167. Weinstein GD. Methotrexate. *Ann Intern Med* 1977; 86:199-204.
 168. Duncan KO, Imaeda S, Milstone LM. Pneumocystis carinii pneumonia complicating methotrexate treatment of pityriasis rubra pilaris. *J Am Acad Dermatol* 1998;39:276-8.
 169. Ahmed AR, Moy R. Azathioprine. *Int J Dermatol* 1981;20:461-7.

170. Hunter GA, Forbes IJ. Treatment of pityriasis rubra pilaris with azathioprine. *Br J Dermatol* 1972;87:42-5.
171. Gendler E. Azathioprine for use in Dermatology. *J Dermatol Surg Oncol* 1984;10:462-4.
172. Rosenbach A, Lowe NJ. Pityriasis rubra pilaris and cyclosporine. *Arch Dermatol* 1993;129:1346-8.
173. Usuki K, Sekiyama M, Shimada T, Shimada S, Kanzaki T. Three cases of pityriasis rubra pilaris successfully treated with cyclosporine A. *Dermatology* 2000;200:324-7.
174. Meyer P, van Voorst Vader PC. Lack of effect of cyclosporine A in pityriasis rubra pilaris. *Acta Derm Venerol* 1989;69:272.
175. Webster JR, Falk AB. Pityriasis rubra pilaris; clinical and laboratory observation on combined treatment with corticotropin and Vitamin A. *AMA Arch Dermatol Syphilol* 1952;65:685-700.
176. Binnick SA. Pityriasis rubra pilaris responding to aminonicotinamide. *Arch Dermatol* 1978;114:1348-9.
177. Griffiths A, Ralfs I. Aminonicotinamide in pityriasis rubra pilaris. *Arch Dermatol* 1981;117:127.
178. Irgang S. Pityriasis rubra pilaris responsive to ascorbic acid. *Australas J Dermatol* 1968;9:211-7.
179. Watt TL, Jilison OF. Pityriasis rubra pilaris: Penicillin and antituberculous drugs as possible therapeutic agents. *Arch Dermatol* 1965;92:428-30.
180. Pavlidakey GP, Hashimoto K, Savoy LB, Heller GL, Iacobelli D, Barfield L. Stanozolol in the treatment of pityriasis rubra pilaris. *Arch Dermatol* 1985;121:546-8.
181. van de Kerkhof PC, de Jong EM. Topical treatment with the Vitamin D3 analogue MC903 improves pityriasis rubra pilaris: clinical and immunochemical observation. *Br J Dermatol* 1991;125:293-4.
182. Van de Kerkhof PC, Steijlen PM. Topical treatment of pityriasis rubra pilaris with calcipotriol. *Br J Dermatol* 1994;130:675-8.
183. Thiers BH. The use of topical calcipotriene-calcipotriol in conditions other than plaque-type psoriasis. *J Am Acad Dermatol* 1997;37:S69-71.
184. Coras B, Vogt TH, Ulrich H, Landthaler M, Hohenleutner U. Fumaric acid esters therapy: A new treatment modality in pityriasis rubra pilaris? *Br J Dermatol* 2005;152:388-9.
185. Haenssle HA, Bertsch HP, Emmert S, Wolf C, Zutt M. Extracorporeal photochemotherapy for the treatment of exanthematic pityriasis rubra pilaris. *Clin Exp Dermatol* 2004;29:244-6.
186. Sehgal VN, Srivastava G, Aggarwal AK, Sardana K, Jain M. Efficacy of isotretinoin in pityriasis rubra pilaris: Unapproved use. *Int J Dermatol* 2006;45:1238-40.
187. Okano M. Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis. *Dermatology* 2001;202:116-8.
188. Gonzalez-Lopez A, Velasco E, Pozo T, Del Villar A. HIV-associated pityriasis rubra pilaris responsive to triple antiretroviral therapy. *Br J Dermatol* 1999;140:931-4.
189. Griffiths WA. Pityriasis rubra pilaris: An historical approach: 2, Clinical features. *Clin Exp Dermatol* 1976;1:37-50.
190. Sardana K, Sehgal VN. Retinoids: Fascinating up-and-coming scenario. *J Dermatol (Tokyo)* 2003;30:355-80.
191. Goldsmith LA, Weinrich AE, Shupack J. Pityriasis rubra pilaris response to 13-cis-retinoic acid (isotretinoin). *J Am Acad Dermatol* 1982;6:710-5.
192. Manoharan S, White S, Gumparthy K. Successful treatment of type I adult-onset pityriasis rubra pilaris with infliximab. *Australas J Dermatol* 2006;47:124-9.
193. Gregoriou S, Argyriou G, Christofidou E, Vranou A, Rigopoulos D. Treatment of pityriasis rubra pilaris with pimecrolimus cream 1%. *J Drugs Dermatol* 2007;6:340-2.